In Burkitt lymphoma [19, 20, 25] and chronic lymphocytic leukemia (CLL) [20, 21], the effect of rituximab was enhanced when antagonizing CXCR4 and, recently, we reported a synergistic effect when administering the CXCR4 antagonist plerixafor concomitantly with rituximab to DLBCL cells in vitro [26]. This evidence concerns the gene CXCR4 and diffuse large B-cell lymphoma.